Cargando…
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to HER3, leading to heterodimerization with other HER/ERBB kinases, increased downstream signaling, and tumorigenesis. Targeting ERBBs, therefore, represents a therapeutic strategy for these cancers. We investigated zeno...
Autores principales: | Schram, Alison M., Odintsov, Igor, Espinosa-Cotton, Madelyn, Khodos, Inna, Sisso, Whitney J., Mattar, Marissa S., Lui, Allan J.W., Vojnic, Morana, Shameem, Sara H., Chauhan, Thrusha, Torrisi, Jean, Ford, Jim, O'Connor, Marie N., Geuijen, Cecile A.W., Schackmann, Ron C.J., Lammerts van Bueren, Jeroen J., Wasserman, Ernesto, de Stanchina, Elisa, O'Reilly, Eileen M., Ladanyi, Marc, Drilon, Alexander, Somwar, Romel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394398/ https://www.ncbi.nlm.nih.gov/pubmed/35135829 http://dx.doi.org/10.1158/2159-8290.CD-21-1119 |
Ejemplares similares
-
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
por: Somwar, Romel, et al.
Publicado: (2020) -
LPTO-04. GENERATION AND CHARACTERIZATION OF PATIENT-DERIVED PRECLINICAL MODELS FROM TUMOR CELLS ISOLATED FROM CEREBROSPINAL FLUID
por: Offin, Michael, et al.
Publicado: (2019) -
RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
por: Hayashi, Takuo, et al.
Publicado: (2021) -
CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma
por: Odintsov, Igor, et al.
Publicado: (2022) -
A blast from the past: ROS1 on the brain
por: Odintsov, Igor, et al.
Publicado: (2019)